P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

July 2011

Features

Pharmacogenomics in Clinical Practice

Reality and Expectations

The cost of DNA sequencing has dropped dramatically since the completion of the Human Genome Project in 2003. However, many barriers need to be overcome in order to translate pharmacogenomic research findings into clinical practice.
C. Lee Ventola, MS

Regulatory Compliance

The ESA APPRISE Oncology Program

A History of REMS Requirements, a Review of the Data, and an Approach to Compliance in the Hospital

Risk Evaluation and Mitigation Strategy (REMS) programs now accompany more than 150 drug products. The ESA APPRISE Oncology Program was implemented to ensure the safe use of erythropoiesis-stimulating agents (ESAs). One hospital’s response to the challenge of meeting compliance criteria involved the creation of a specific medication order set.
David J. Reeves, PharmD, BCOP; Amanda K. Quebe, PharmD; and Ranita Patel, PharmD

Perspective

The Value of Branded Proton Pump Inhibitors

Formulary Considerations

Newer-generation branded proton pump inhibitors (PPIs) have shown some advantages over generic PPIs in the treatment of gastroesophageal reflux disease. These differences are discussed along with ways of incorporating the newer PPIs into formularies.
David A. Peura, MD; Rosemary R. Berardi, PharmD; Javier Gonzalez, PharmD; and Louis Brunetti, MD, JD

Meeting Highlights

American Society of Hypertension and European Congress of Rheumatology/European League Against Rheumatism

Sessions on hypertension focus on four fixed-dose clinical trials and the effects of coffee and caffeine. The EULAR meeting includes news about pegloticase (Krystexxa) for gout; tofacitinib, an investigational oral biologic for rheumatoid arthritis; and anti–tumor necrosis factor therapy for arthritis.
Walter Alexander

Departments

Medication Errors

A Fatal Zinc Overdose in a Neonate

Confusion of Micrograms With Milligrams

A fatal zinc overdose in a newborn caused by confusion of micrograms versus milligrams
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Critics Assail FDA Medical Device Approval Process

Slow Review Time and Safety Are at Issue

Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Fidaxomicin (Dificid) for fecal incontinence, rilpivirine (Edurant) for HIV-1 infection, and boceprevir (Victrelis) for patients with chronic hepatitis C virus genotype 1 infection
Marvin M. Goldenberg, PhD, RPh, MS